Parameter | All patients (n = 50) | PH score ≤ 3 (n = 24) | PH score ≥ 4 (n = 26) | P value |
---|---|---|---|---|
Age, Median (IQR) | 68 (62 – 73) | 70 (65 – 76) | 64 (61 – 71) | 0.025 |
Sex, n (%) | 0.832 | |||
Female | 10 (20.0) | 4 (16.7) | 6 (23.1) | |
Male | 40 (80.0) | 20 (83.3) | 20 (76.9) | |
Etiology of cirrhosis, n (%) | 0.816 | |||
Alcohol | 19 (38.0) | 9 (37.5) | 10 (38.5) | |
Viral | 7 (14.0) | 2 (8.3) | 5 (19.2) | |
Other | 11 (22.0) | 6 (25.0) | 5 (19.2) | |
No cirrhosis | 13 (26.0) | 7 (29.2) | 6 (23.1) | |
Child–Pugh stage, n (%) | 0.266 | |||
A | 25 (50.0) | 14 (58.3) | 11 (42.3) | |
B | 10 (20.0) | 3 (12.5) | 7 (26.9) | |
C | 2 (4.0) | 0 | 2 (7.7) | |
No cirrhosis | 13 (26.0) | 7 (29.2) | 6 (23.1) | |
ECOG, n (%) | 1.000 | |||
≤ 1 | 47 (94.0) | 23 (95.8) | 24 (92.3) | |
2 | 3 (6.0) | 1 (4.2) | 2 (7.7) | |
BCLC stage, n (%) | 0.797 | |||
B | 5 (10.0) | 2 (8.3) | 3 (11.5) | |
C | 42 (84.0) | 21 (87.5) | 21 (80.8) | |
D | 3 (6.0) | 1 (4.2) | 2 (7.7) | |
Portal vein invasion, n (%) | 0.991 | |||
Yes | 26 (52.0) | 13 (54.2) | 13 (50.0) | |
No | 24 (48.0) | 11 (45.8) | 13 (50.0) | |
Distant metastasis, n (%) | 1.000 | |||
Yes | 25 (50.0) | 12 (50.0) | 13 (50.0) | |
No | 25 (50.0) | 12 (50.0) | 13 (50.0) | |
Focality of the liver lesions, n (%) | 1.000 | |||
Unifocal | 11 (22.0) | 6 (25.0) | 5 (19.2) | |
Multifocal | 39 (78.0) | 18 (75.0) | 21 (80.8) | |
Sum of the size of the target lesions, mm, Median (IQR) | 83 (51 – 135) | 58 (45 – 122) | 97 (59 – 149) | 0.205 |
AFP, ng/ml, Median (IQR) | 277 (16 – 4485) | 84 (12 – 1467) | 60 (1240 – 18,359) | 0.071 |
Albumin, g/l, Median (IQR) | 30 (27 – 33) | 33 (30 – 36) | 28 (25 – 30) | < 0.001 |
Bilirubin, mg/dl, Median (IQR) | 1.5 (0.7 – 2.3) | 0.8 (0.6 – 1.7) | 2.2 (1.5 – 3.1) | < 0.001 |
INR, Median (IQR) | 1.2 (1.1 – 1.3) | 1.2 (1.1 – 1.4) | 1.2 (1.1 – 1.3) | 0.984 |
Creatinine, mg/dl | 0.9 (0.7 – 1.1) | 0.8 (0.7 – 1.0) | 0.9 (0.7 – 1.2) | 0.431 |
Immunotherapeutic agent, n (%) | ||||
atezolizumab + bevacizumab | 29 (58.0) | 17 (70.8) | 12 (46.2) | 0.201 |
pembrolizumab | 11 (22.0) | 3 (12.5) | 7 (26.9) | |
nivolumab | 10 (20.0) | 4 (16.7) | 7 (26.9) | |
Line of systemic treatment, n (%) | 0.107 | |||
First | 29 (58.0) | 17 (70.8) | 12 (46.2) | |
Second | 11 (22.0) | 5 (20.8) | 6 (23.1) | |
Third | 10 (20.0) | 2 (8.3) | 8 (30.7) | |
Previous therapy, n (%) | 0.200 | |||
Yes | 42 (84.0) | 18 (75.0) | 24 (92.3) | |
No | 8 (16.0) | 6 (25.0) | 2 (7.7) |